New blood biomarkers for the diagnosis of Alzheimer's

• DOI: https://doi.org/10.22533/at.ed.1594602426065

• Palavras-chave: Alzheimer's Disease; Early Diagnosis; Biomarkers.

• Keywords: Alzheimer's Disease; Early Diagnosis; Biomarkers.

• Abstract:

  Objective: To identify and evaluate recent advances in the discovery of blood biomarkers for early diagnosis and monitoring of the progression of Alzheimer's disease, highlighting their clinical potential, sensitivity, specificity and feasibility for large-scale use. Methods: Bibliographic review carried out in the PubMed database using the search strategy: (Alzheimer's Disease) AND (Early Diagnosis) AND ((Biomarkers) OR (Blood Biomarkes)). It resulted in the selection of 19 articles from a total of 468 initially identified, based on strict inclusion and exclusion criteria Review: The potential usefulness of plasma biomarkers such as Tau protein, NFL, and beta-amyloid peptides (Aβ42 and Aβ40) is highlighted), which were shown to reflect the pathological processes of the disease and offer a less invasive diagnostic approach. Furthermore, technologies such as mass spectrometry and antibody-based assays have been identified as essential for advancing the accurate identification of these biomarkers. Final considerations: We highlight the need for more research to validate the clinical applicability of these biomarkers in different populations and stages of the disease, with the aim of integrating them effectively in the diagnosis and monitoring of Alzheimer's disease.